FDA Approves Nasacort HFA for Allergic Rhinitis
Nasacort HFA (triamcinolone acetonide) is a dry-aerosol intranasal corticosteroid formulation containing hydrofluoroalkane (HFA). It replaces Nasacort Nasal Inhaler, which along with other nasal inhalers containing CFC’s, was taken off the market to comply with Environmental Protection Agency (EPA) and FDA requirements intended to protect the ozone layer. Nasacort HFA Nasal Aerosol is indicated for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and children age 6 and older.Posted: April 2004
Related articles
- FDA Approves Sanofi's Nasacort Allergy 24HR for Over-the-Counter Use - October 11, 2013
- FDA Approves Nasacort AQ Nasal Spray for Children Aged 2-5 years old - September 23, 2008
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
